FDA approves BB Biotech backed Agios’ AML drug Tibsovo Agios Pharmaceuticals (NASDAQ:AGIO), a top 10 holding for Switzerland’s BB Biotech (BBB), has received US FDA approval for Tibsovo for relapsed or refractory acute myeloid leukaemia (r/r AML) with a specific IDH1 mutation. Agios, which has seen its shares rise by ~50% this year, accounted for […]
FDA accepts HBM investee Immunomedics’ breast cancer drug filing US biotech Immunomedics (Nasdaq:IMMU), a top 10 holding for Swiss-listed HBM Healthcare (2.5% of NAV), has reported that the US FDA has accepted its regulatory application for the antibody-drug conjugate sacituzumab govitecan and granted priority review with an action date of 18 January 2019. The application […]
Trust favourite Biogen preps for detailed Alzheimer’s trial results Trust favourite Biogen (Nasdaq: BIIB), the largest single holding for Biotech Growth Trust (BIOG, 11.7% of NAV) and widely held stock among other sector specialist collective vehicles – will with its joint venture partner Eisai shortly disclose detailed results from a Phase II study of the […]
Polar Capital Healthcare rejigs portfolio Polar Capital Global Healthcare Trust (PCGH) has disclosed a significant portfolio rejig in its end June monthly update, noting that it had sold a number of positions and increased its cash holdings partly on concerns about increased volatility in the equity markets and the potential for a market correction over the summer. […]
HBM-backed Argenx gets Shire as partner Dutch antibody company Argenx (Euronext & Nasdaq:ARGX), a top ten holding for Swiss-listed HBM Healthcare (HBMN, 2.9% of NAV), has gained a new licensing partner with the exercise by Shire Pharmaceuticals of an option held under a 2012 discovery alliance. The license covers a a preclinical stage antibody discovered and […]
Genmab commits to new bispecific cancer immunotherapy programme Danish biotech Genmab (Nasdaq Copenhagen: GEN) has paid $54m upfront and committed to pay up to $1.65bn in R&D, regulatory and commercial milestones to the private German biotech Immatics as part of a deal to discover and develop three next-generation bispecific cancer immunotherapies. Genmab, which is Europe’s […]
EC approves Ionis’ amyloidosis drug Ionis Pharmaceuticals (Nasdaq: IONS) has received marketing authorisation from the European Commission for Tegsedi (inotersen), its RNA-targeted therapeutic for stage 1 or 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR). This is the first approval for the drug and unusually EU approval has come through ahead of the US, with the outcome of […]
Celgene claims win for luspatercept in Believe trial Specialist trust favourite Celgene (Nasdaq: CELG) has reported positive result in a Phase III trial with the drug candidate luspatercept for treatment of anaemia associated with beta-thalassemia. This follows the company’s success in the Medalist Phase III trial win with the same drug in anaemia associated with myelodysplastic syndrome (MDS). The unambiguous […]
Key regulatory updates biotech specialist trust investees Two stocks that core holdings for biotech specialist trusts have reported important regulatory updates in the past week, with several other companies approaching key events, as detailed below. Array BioPharma (Nasdaq: ARRY), a top ten holding for International Biotechnology Trust (IBT), received FDA approval for Braftovi in combination with Mektovi […]
Arix, Syncona and WPCT bank gains after Autolus “pops” on Nasdaq IPO Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) should be able to record some sizeable NAV gains this month, as previously highlighted in earlier Quoteddata.com articles, on the back of a revaluation to market value of their respective holdings in the common portfolio […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated